Abstract
Background: Herbomineral formulations are being successfully used in Ayurvedic therapeutics since centuries. Though the preclinical safety of these formulations is established, there have been reports questioning the safety of their metallic contents, especially the presence of heavy metals. As such, it becomes imperative for the contemporary practitioners of Ayurveda to document and publish their observations on the safety of classical herbomineral formulations; as such studies will enable the scientific community to believe traditional systems too as evidence based on account of safety and efficacy.
Aim: The current work was an observational study in effort to document the safety of Chandraprabha Vati with objective
to review and report dose related adverse effects and its safety.
Method: The study data was collected from the hospital software records to survey the prescription patterns in the regular OPD and also to report any untoward affects of Chandraprabha Vati. The dose related adverse effects / safety of Chandraprabha Vati were reviewed and the observations were reported.
Results & Conclusion: There were no serious adverse reactions or toxicity symptoms with Chandraprabha Vati administered orally at doses of 500-1000 mg/ day given over 1 - 4 months.
Conclusion: Chandraprabha Vati, an Ayurvedic metallo-herbo- mineral formulation is safe when administered in prescribed doses.

Key words: Chandraprabha Vati, Heavy metal, Herbomineral, Safety

Similar Articles

A protein-sulfosalicylic acid/boswellic acids @metal-organic framework nanocomposite as anticancer drug delivery system.
Özsoy M, Atiroğlu V, Guney Eskiler G, Atiroğlu A, Deveci Ozkan A, Özacar M
Colloids and surfaces. B, Biointerfaces. 2021; 204(): 111788

Evaluation of the Efficacy and Safety of an eGlycemic Management System in a Community Hospital Setting.
Bouldin MG, Hong B, Setji T, Greenlee J, Cooper A, Thompson J, Capes K
Journal of diabetes science and technology. 2021; 15(2): 236-241

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A,
United European gastroenterology journal. 2021; 9(1): 102-109

Reduction of Norovirus Surrogates Alone and in Association with Bacteria on Leaf Lettuce and Tomatoes During Application of Aqueous Ozone.
Dawley CR, Lee JA, Gibson KE
Food and environmental virology. 2021; ():

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Kappos L, Cohan S, Arnold DL, Robinson RR, Holman J, Fam S, Parks B, Xiao S, Castro-Borrero W
Therapeutic advances in neurological disorders. 2021; 14(): 1756286420987941